Featured Publications
Stroke Code Presentations, Interventions, and Outcomes Before and During the COVID-19 Pandemic
Jasne AS, Chojecka P, Maran I, Mageid R, Eldokmak M, Zhang Q, Nystrom K, Vlieks K, Askenase M, Petersen N, Falcone GJ, Wira CR, Lleva P, Zeevi N, Narula R, Amin H, Navaratnam D, Loomis C, Hwang DY, Schindler J, Hebert R, Matouk C, Krumholz HM, Spudich S, Sheth KN, Sansing LH, Sharma R. Stroke Code Presentations, Interventions, and Outcomes Before and During the COVID-19 Pandemic. Stroke 2020, 51: 2664-2673. PMID: 32755347, PMCID: PMC7446978, DOI: 10.1161/str.0000000000000347.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overBetacoronavirusBrain IschemiaCohort StudiesComorbidityConnecticutCoronary Artery DiseaseCoronavirus InfectionsCOVID-19DyslipidemiasEmergency Medical ServicesEthnicityFemaleHumansHypertensionIncomeInsurance, HealthIntracranial HemorrhagesMaleMedically UninsuredMiddle AgedOutcome and Process Assessment, Health CarePandemicsPneumonia, ViralRetrospective StudiesSARS-CoV-2Severity of Illness IndexStrokeSubstance-Related DisordersTelemedicineThrombectomyThrombolytic TherapyTime-to-TreatmentConceptsComprehensive stroke centerStroke codePatient characteristicsStroke severityStroke code patientsHistory of hypertensionStroke-like symptomsCoronary artery diseaseCoronavirus disease 2019 (COVID-19) pandemicPatient-level dataLower median household incomePublic health initiativesDisease 2019 pandemicCOVID-19 pandemicRace/ethnicityCode patientsHospital presentationPublic health insuranceRankin ScaleStroke centersArtery diseaseReperfusion timeStroke symptomsEarly outcomesConnecticut hospitals
2024
Adjunctive Intravenous Argatroban or Eptifibatide for Ischemic Stroke
Adeoye O, Broderick J, Derdeyn C, Grotta J, Barsan W, Bentho O, Berry S, Concha M, Davis I, Demel S, Elm J, Gentile N, Graves T, Hoffman M, Huang J, Ingles J, Janis S, Jasne A, Khatri P, Levine S, Majjhoo A, Panagos P, Pancioli A, Pizzella S, Ranasinghe T, Sabagha N, Sivakumar S, Streib C, Vagal A, Wilson A, Wintermark M, Yoo A, Barreto A. Adjunctive Intravenous Argatroban or Eptifibatide for Ischemic Stroke. New England Journal Of Medicine 2024, 391: 810-820. PMID: 39231343, DOI: 10.1056/nejmoa2314779.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAnticoagulantsArginineCombined Modality TherapyDrug Therapy, CombinationEptifibatideFemaleFibrinolytic AgentsHumansIncidenceInfusions, IntravenousIntracranial HemorrhagesIschemic StrokeMaleMiddle AgedPeptidesPipecolic AcidsPlatelet Aggregation InhibitorsSingle-Blind MethodSulfonamidesThrombectomyThrombolytic TherapyTreatment OutcomeConceptsSymptomatic intracranial hemorrhageIntravenous argatrobanIntravenous thrombolysisAcute ischemic strokeIntracranial hemorrhageIschemic strokeIncidence of symptomatic intracranial hemorrhageSymptom onsetIschemic stroke treated with intravenous thrombolysisAcute ischemic stroke treated with intravenous thrombolysisStroke treated with intravenous thrombolysisAssociated with increased mortalityRankin Scale scoreInitiation of thrombolysisControlled clinical trialsTreatment of acute ischemic strokePlacebo groupEptifibatide groupEfficacy outcomesArgatroban groupStandard treatmentAdjunctive treatmentPlaceboClinical trialsArgatroban